{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:46:34Z","timestamp":1791341194597,"version":"4.3.1"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A study was designed to assess the impact of the VITEK 2 automated system and the Advanced Expert System (AES) on the clinical laboratory of a typical university-based hospital. A total of 259 consecutive, nonduplicate isolates of\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            members,\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            , and\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            were collected and tested by the VITEK 2 system for identification and antimicrobial susceptibility testing, and the results were analyzed by the AES. The results were also analyzed by a human expert and compared to the AES analyses. Among the 259 isolates included in this study, 245 (94.6%) were definitively identified by VITEK 2, requiring little input from laboratory staff. For 194 (74.9%) isolates, no inconsistencies between the identification of the strain and the antimicrobial susceptibility determined by VITEK 2 were detected by the AES. Thus, no input from laboratory staff was required for these strains. The AES suggested one or more corrections to results obtained with 65 strains to remove inconsistencies. The human expert thought that most of these corrections were appropriate and that some resulted from a failure of the VITEK 2 system to detect certain forms of resistance. Antimicrobial phenotypes assigned to the strains by the AES for \u03b2-lactams, aminoglycosides, quinolones, macrolides, tetracyclines, and glycopeptides were similar to those assigned by the human expert for 95.7 to 100% of strains. These results indicate that the VITEK 2 system and AES can provide accurate information in tests for most of the clinical isolates examined and remove the need for human analysis of results for many. Certain problems were identified in the study that should be remediable with further work on the software supporting the AES.\n          <\/jats:p>","DOI":"10.1128\/jcm.39.7.2379-2385.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:23Z","timestamp":1027764383000},"page":"2379-2385","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital"],"prefix":"10.1128","volume":"39","author":[{"given":"Christine C.","family":"Sanders","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Peyret","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->bioMe\u0301rieux Inc., Hazelwood, Missouri 630422; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen Smith","family":"Moland","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Cavalieri","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Department of Pathology,3 Creighton University School of Medicine, Omaha, Nebraska 68178;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Shubert","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->bioMe\u0301rieux Inc., Hazelwood, Missouri 630422; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Thomson","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Boeufgras","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->bioMe\u0301rieux, LaBalme-Les-Grottes, France4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"W. Eugene","family":"Sanders","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050429"},{"key":"e_1_3_2_3_2","unstructured":"National Committee for Clinical Laboratory Standards\nMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7\u2013A4.\n1997\nNational Committee for Clinical Laboratory Standards\nVillanova Pa"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.2.335"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.1.4.283"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1893"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.2.570-574.2000"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Thomson\nK. S.\nBakken\nJ. S.\nSanders\nC. C.\nAntimicrobial susceptibility testing within the clinic\nMicrobiological quality assurance: a guide towards relevance and reproducibility of inocula.\nBrown\nM. R. W.\nGilbert\nP.\n1995\n275\n288\nCRC Press Inc.\nNew York N.Y","DOI":"10.1201\/9781351074551-18"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0923-2508(96)81390-8"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.39.7.2379-2385.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.39.7.2379-2385.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T01:13:19Z","timestamp":1646442799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.39.7.2379-2385.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1128\/JCM.39.7.2379-2385.2001"],"URL":"https:\/\/doi.org\/10.1128\/jcm.39.7.2379-2385.2001","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]},"assertion":[{"value":"2000-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}